Effect of Empagliflozin on Muscle Sympathetic Nerve Activity (MSNA) in Patients with Type 2 Diabetes (T2DM) Despite Reductions in Blood Pressure (BP) and Weight

Trial Profile

Effect of Empagliflozin on Muscle Sympathetic Nerve Activity (MSNA) in Patients with Type 2 Diabetes (T2DM) Despite Reductions in Blood Pressure (BP) and Weight

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2015

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top